Futu News, September 19, biotechnology company $Exicure (XCUR.US)$ It rose sharply before the market opened today. As of the time of publication, the stock is up 171.62% to $6.22, with pre-market trading volume reaching $3.6531 million, and a pre-market surge of more than 295%.

On the news front, the company announced yesterday that it received a notice from the NASDAQ hearing panel on September 17, approving the extension of the company's listing qualification, but the company must demonstrate its compliance with all applicable listing standards of the NASDAQ capital market by November 14, 2024. The company is working hard to meet the panel's requirements in a timely manner and ensure its continued listing on the NASDAQ.

In addition, the company has regained compliance with NASDAQ's minimum bid price requirement and has converted approximately $1 million of debt into equity at a price of $3.00 per share.

About the company

Exicure is a clinical-stage biotechnology company that has developed therapies for neurology, immuno-oncology, inflammatory diseases, and genetic diseases based on its proprietary spherical nucleic acid (SNA) technology.

It is worth mentioning that according to Futu News, there are many instances of small market cap US stocks experiencing significant volatility due to the absence of price limits, posing higher risks for investors who should therefore be cautious.